NEW YORK (GenomeWeb) – Epistem announced this week the completion of the management buyout of Genedrive following an undisclosed investment by Foresight Group. Epistem provides preclinical and clinical research services across specialist therapeutic areas, such as oncology, gastrointestinal diseases, and toxicity and inflammatory diseases. Foresight's investment will enable Epistem to expand its next-generation sequencing and laser-capture technologies, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.